Edition:
United States

Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

25.57USD
26 May 2017
Change (% chg)

$-0.88 (-3.33%)
Prev Close
$26.45
Open
$26.33
Day's High
$26.39
Day's Low
$25.52
Volume
20,735
Avg. Vol
396,373
52-wk High
$41.69
52-wk Low
$23.07

XLRN.O

Chart for XLRN.O

About

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta... (more)

Overall

Beta: 1.73
Market Cap(Mil.): $1,021.44
Shares Outstanding(Mil.): 38.62
Dividend: --
Yield (%): --

Financials

  XLRN.O Industry Sector
P/E (TTM): -- 141.29 17.43
EPS (TTM): -2.31 -- --
ROI: -35.83 2.17 -5.41
ROE: -37.34 0.10 -4.69

BRIEF-Acceleron Pharma qtrly loss per share $0.66

* Acceleron pharma reports first quarter 2017 operational and financial results

May 08 2017

BRIEF-Acceleron announces management change

* Acceleron Pharma Inc - Steven Ertel, due to medical reasons, will transition from his role as executive vice president and chief operating officer

May 02 2017

BRIEF-Acceleron says enrolment for late stage studies now expected to be completed in Q2

* Acceleron provides clinical development updates on luspatercept program

Apr 27 2017

BRIEF-Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease

* Acceleron announces plans to initiate a phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease and host educational webinar

Mar 16 2017

BRIEF-Acceleron outlines corporate goals and priorities for 2017

* Plan to initiate new luspatercept phase 2 clinical trials in distinct patient segments in MDS and Beta-Thalassemia

Jan 06 2017

More From Around the Web

Earnings vs. Estimates